METHOD OF TREATING ENDOTHELIAL INJURY

• US 20080124401A1
• Filed: 06/29/2007
• Published: 05/29/2008
• Est. Priority Date: 09/11/1996
• Status: Active Grant

• Current Assignee: East Carolina University
• Original Assignee: East Carolina University
• Inventors: Anagnostou, Athanasius A., Sigounas, George
• Granted Patent: US 7,803,408 B2
• Time in Patent Office: Days
• US Class Current: 424/649
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

The use of human erythropoietin (EPO) to prevent or treat endothelial injury due to chemotherapy, radiation therapy, mechanical trauma, or to a disease state which damages the endothelium (such as inflammation, heart disease or cancer) is described. The use of EPO in conjunction with the administration of chemotherapeutic agents is described.

Claims

1. A method of treating a solid vascularized tumor in a subject in need of such treatment, comprising administering erythropoietin in conjunction with a chemotherapeutic agent, wherein said erythropoietin is administered in an amount effective to enhance suppression of endothelial growth associated with administration of said chemotherapeutic agent, wherein said amount is a dosage in a range of 750 Units per kilogram to 2000 Units per kilogram.

2. The method of claim 1, wherein said chemotherapeutic agent is administered in a manner selected from the group consisting of intravenous, intramuscular, intraperitoneal, subcutaneous, intratumor, and intrapleural injection.

3. The method of claim 1, wherein said chemotherapeutic agent is cisplatin, carboplatin or mitomycin.

4. The method of claim 1, wherein said erythropoietin is administered intravenously or subcutaneously.

5. The method of treating a solid vascularized tumor of claim 1, wherein said subject is afflicted with a solid vascularized tumor selected from cerebellar hemangioblastoma, ductal carcinoma of the breast or squamous cell cancer of the larynx.

6. A method of treating a solid vascularized tumor in a subject in need of such treatment, comprising administering erythropoietin in conjunction with cisplatin;

wherein said erythropoietin is administered in an endothelial growth suppressing amount, wherein said amount is a dosage in a range from about 750 Units per kilogram to about 2,000 Units per kilogram.

7. The method of claim 6, wherein said cisplatin is administered intravenously.

8. The method of claim 6, wherein said erythropoietin is administered intravenously or subcutaneously.

9. The method of treating a solid vascularized tumor of claim 6, wherein said subject is afflicted with a solid vascularized tumor selected from cerebellar hemangioblastoma, ductal carcinoma of the breast, or squamous cell cancer of the larynx.

10. The method of claim 9, wherein the solid vascularized tumor is a cerebellar hemangioblastoma.

11. The method of claim 9, wherein the solid vascularized tumor is a ductal carcinoma of the breast.

12. The method of claim 9, wherein the solid vascularized tumor is a squamous cell cancer of the larynx.